SageView Advisory Group’s Pacific Biosciences PACB Stock Holding History

SageView Advisory Group’s Portfolio PACB Stock Details PACB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	$193	Buy	+103	New	+$198	﹤0.01%	2514

Other funds holding PACB

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

SageView Advisory Group's PACB Position: Q4 2025 in Review

SageView Advisory Group opened a new position in Pacific Biosciences (PACB) in Q4 2025: 103 shares worth $193. The stake represents ﹤0.01% of the portfolio and ranks #2514 among its holdings.

215 funds tracked by Wall St. Rank hold PACB as of Q4 2025.

SageView Advisory Group held 103 shares of Pacific Biosciences worth $193 as of Q4 2025.
Pacific Biosciences was a new SageView Advisory Group position in Q4 2025.
Pacific Biosciences made up ﹤0.01% of SageView Advisory Group's portfolio in Q4 2025, its #2514 holding.
215 funds tracked by Wall St. Rank held Pacific Biosciences as of Q4 2025.

Based on SageView Advisory Group's 13F filing for Q4 2025, filed 17 Feb 2026.